These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 27990643)
1. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. Guptill JT; Raja SM; Boakye-Agyeman F; Noveck R; Ramey S; Tu TM; Laskowitz DT J Clin Pharmacol; 2017 Jun; 57(6):770-776. PubMed ID: 27990643 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury. James ML; Komisarow JM; Wang H; Laskowitz DT Neurotherapeutics; 2020 Apr; 17(2):475-483. PubMed ID: 32318912 [TBL] [Abstract][Full Text] [Related]
3. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. Kirzinger L; Boy S; Marienhagen J; Schuierer G; Neu R; Ried M; Hofmann HS; Wiebe K; Ströbel P; May C; Kleylein-Sohn J; Baierlein C; Bogdahn U; Marx A; Schalke B PLoS One; 2016; 11(12):e0168215. PubMed ID: 27992479 [TBL] [Abstract][Full Text] [Related]
4. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. Poveda E; Hernández-Quero J; Pérez-Elías MJ; Ribas MA; Martínez-Madrid OJ; Flores J; Navarro J; Gutiérrez F; García-Deltoro M; Imaz A; Ocampo A; Artero A; Blanco F; Bernal E; Pasquau J; Mínguez-Gallego C; Pérez N; Aiestaran A; García F; Paredes R; HIV Med; 2017 Aug; 18(7):482-489. PubMed ID: 28035758 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993 [TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor-Like 1 (ORL-1) Partial Agonist, in Patients With Isolated Systolic Hypertension. Kantola I; Scheinin M; Gulbrandsen T; Meland N; Smerud KT Clin Pharmacol Drug Dev; 2017 Nov; 6(6):584-591. PubMed ID: 28032481 [TBL] [Abstract][Full Text] [Related]
8. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder. Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835 [TBL] [Abstract][Full Text] [Related]
9. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. Taylor L; Gidal B; Blakey G; Tayo B; Morrison G CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective Pentapeptide, CN-105, Improves Outcomes in Translational Models of Intracerebral Hemorrhage. Wang H; Faw TD; Lin Y; Huang S; Venkatraman TN; Cantillana V; Lascola CD; James ML; Laskowitz DT Neurocrit Care; 2021 Oct; 35(2):441-450. PubMed ID: 33474632 [TBL] [Abstract][Full Text] [Related]
11. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects. Ermer J; Martin P; Corcoran M; Matsuo Y Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110 [TBL] [Abstract][Full Text] [Related]
12. ApoE Mimetic Peptides as Therapy for Traumatic Brain Injury. Laskowitz DT; Van Wyck DW Neurotherapeutics; 2023 Oct; 20(6):1496-1507. PubMed ID: 37592168 [TBL] [Abstract][Full Text] [Related]
13. Are We Ready for Clinical Therapy based on Cerebral Autoregulation? A Pro-con Debate. Sarwal A; Robba C; Venegas C; Ziai W; Czosnyka M; Sharma D Neurocrit Care; 2023 Oct; 39(2):269-283. PubMed ID: 37165296 [TBL] [Abstract][Full Text] [Related]
14. Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers. Lodise TP; O'Donnell JN; Raja S; Guptill JT; Zaharoff S; Schwager N; Fowler VG; Beresnev T; Wall A; Wiegand K; Serti Chrisos E; Balevic S; Chambers HF; Antimicrob Agents Chemother; 2022 Dec; 66(12):e0093522. PubMed ID: 36394316 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic treatment with CN-105 improves functional outcomes in a murine model of closed head injury. Van Wyck D; Kolls BJ; Wang H; Cantillana V; Maughan M; Laskowitz DT Exp Brain Res; 2022 Sep; 240(9):2413-2423. PubMed ID: 35841411 [TBL] [Abstract][Full Text] [Related]
16. Remembering your A, B, C's: Alzheimer's disease and ABCA1. Lewandowski CT; Laham MS; Thatcher GRJ Acta Pharm Sin B; 2022 Mar; 12(3):995-1018. PubMed ID: 35530134 [TBL] [Abstract][Full Text] [Related]
17. The role of L-arginine metabolism in neurocritical care patients. Mader MM; Czorlich P Neural Regen Res; 2022 Jul; 17(7):1446-1453. PubMed ID: 34916417 [TBL] [Abstract][Full Text] [Related]